Distributing since 1889 • Employee Owned for Better Service
Your 1st Choice!
Sign In
Quick Search:
Cart
|
My Account
|
Print
Ordering
Advanced Search
Fast Order Entry
Express Order Entry
Can't Find Title?
Shopping Cart
Lists
New Receipts
Recall Information
Forthcoming Titles
Latest Price Changes
Downloads
About Us
Home Page
About Matthews
Return Policy
New Account Application
Publisher List
McCoy Medical
Med-Book
Contact Us
Job Opportunities
FAQ
Terms of Use
Product Detail
NOTICE: This is the ProQuest Ebook Central� format of this title.
What is ProQuest Ebook Central�?
Other formats:
Hardcover
All Formats
Development of Antibody-Based Therapeutics: Translational Considerations
Tabrizi, Mohammad A.
Pricing & Availability
Available: Yes*
This title does not qualify for any discount.
Email this title to a friend
Printer friendly version
Other formats:
Hardcover
All Formats
Book Information
Edition:
1st
Publisher:
Springer
ISBN:
1-4419-5955-6 (1441959556)
ISBN-13:
978-1-4419-5955-3 (9781441959553)
Binding:
E E Book + ProQuest Ebook Central
Copyright:
2012
Publish Date:
06/12
Weight:
0.00 Lbs.
Subject Class:
RET (Returns)
Remarks:
A New Edition of this Title is Available
Return Policy:
Non-Returnable.
Table Of Contents:
View
ProQuest Ebook Central�:
Please sign in to preview this title
Class Specifications
Abstract:
Development of Antibody-Based Therapeutics: Translational Considerations examines important considerations necessary for the design of effective translational strategies during the development of antibody-based therapeutics. Translational strategies for development of antibody-based therapeutics require an understanding of the relationship between the .unit dose' and .unit effect' with respect to both beneficial and deleterious biological effects from early stages of development. The flow of information across various stages of development should provide opportunities to facilitate selection of more effective novel and next-generation drug candidates. Successful strategies for the development of monoclonal antibodies require integration of knowledge with regards to target antigen properties in health and disease, as well as antibody design criteria including affinity, isotype selection, pharmacokinetics/pharmacodynamics (PK/PD) properties, antibody cross-reactivity across species, and safety. Selection and evaluation of appropriate biomarkers in early preclinical development in "relevant" animal models should allow identification of potential risks and liabilities of an antibody drug candidate to humans and establishment of safe First-In-Human (FIH) dosing strategies. This volume provides a comprehensive review of the topics critical for establishing successful translational strategies for the development of antibody-based therapeutics.
* Subject to ProQuest Ebook Central� availability
Follow Matthews Book Co. on:
Copyright © 2001-2024 Matthews Book Company - All rights reserved. - 11559 Rock Island Ct., Maryland Heights, MO, 63043 - (800) MED-BOOK
Matthews
Privacy Statement